For NSCLC: 150mg OD before food. Pancreatic Cancer: 100mg OD before food [with gemcitabine].
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Kinase inhibitor that inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor [EGFR]. Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.
It is metabolized predominantly by CYP3A4 hence inhibitors of CYP3A